MN-ASI-DATAMYTE
11.12.2015 11:01:06 CET | Business Wire | Press release
ASI DATAMYTE, Inc., the leader in global quality management solutions, announces today a multinational partnership with NEXTSENSE GmbH, the leader in the production of laser-based profile measurement solutions for manufacturers, worldwide. The automotive industry is evolving with more complex designs using a broader variety of materials; which is creating the need for a more comprehensive measurement solutions for ensuring accuracy, inspection thoroughness and operator repeatability. As part of this new relationship, ASI DATAMYTE will now support this market need by offering CALIPRI product line to the automotive industry.
“CALIPRI is one of the fastest-growing, scalable, non-contact measurement solutions in the market,” said Sven Tetzlaff, ASI DATAMYTE GmbH head of product and general manager. “We are confident the combination of CALIPRI and our expertise, technology and client base, creates unmatched value for automotive companies looking to produce higher quality products. We will now have a streamlined solution using one technology supporting the inline and automated measurement throughout the production process.”
“We are committed to continuing our investments and innovation in our state-of-the-art optical sensor technology that will empower the future of ASI DATAMYTE’s clients and distributors,” said Clemens Gasser, chief executive officer, NEXTSENSE GmbH. “We are looking forward to watching our partnership redefine quality measurement and data collection across the globe.”
About ASI DATAMYTE
ASI DATAMYTE Inc. provides integrated software, hardware and services for driving best-in-class quality in manufacturing. Refining its solutions for more than 40 years, ASI DATAMYTE is serving the largest, most prestigious manufacturers with localized solutions on a global basis. ASI DATAMYTE is headquartered in Plymouth, MN, with offices and support centers in more than 40 countries.
About NEXTSENSE
NEXTSENSE GmbH is a global leader in producing and distributing revolutionary solutions for profile measurement and surface inspection, called CALIPRI and SURFILES. All solutions are based on non-contact measurement technology which captures unbiased measurement data removing all outside variables based on differences between operators or environmental conditions. NEXTSENSE devices are used for gap and flush measurement of automotive bodies, wear measurement of railway wheelsets and analyzing the surfaces of rolled steel. The client list ranges from international automobile manufactures (e.g. Volkswagen, Toyota, General Motors) to well-known international enterprises in the railway, steel and technology industry such as SNCF, AcelorMittal and Miele).
View source version on businesswire.com: http://www.businesswire.com/news/home/20151211005140/en/
Contact:
ASI DATAMYTE Inc.
Mary Braunwarth
mary.braunwarth@asidatamyte.com
+1.763.553.0455
info@asidatamyte.com
www.asidatamyte.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom